공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

신증후군 : 파이프라인 리뷰

Nephrotic Syndrome (Genitourinary Disorders) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 361632
페이지 정보 영문 64 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


신증후군 : 파이프라인 리뷰 Nephrotic Syndrome (Genitourinary Disorders) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 64 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

신증후군은 과다한 단백뇨를 배출하는 신장질환입니다. 신증후군은 보통 혈액으로부터 노폐물과 과잉수를 여과하고 있는 신장의 미소혈관 다발이 손상되어 발병합니다. 증상은 과다한 체액 울혈에 의한 부종과 체중 증가입니다. 위험요인은 당뇨병, 붉은 반점성 낭창, 아밀로이드증, HIV, B형 간염, C형 간염, 말라리아, 특정 약물(비스테로이드성 항염증제, 항감염증제) 등입니다.

신증후군(Nephrotic Syndrome) 치료제 개발 상황에 대해 조사했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 및 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스/프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

신증후군 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • AbbVie Inc
  • 아사히화성 파마
  • Bristol-Myers Squibb Company
  • Orbis Biosciences Inc
  • Retrophin Inc

약제 개요

신증후군 : 휴지 상태인 프로젝트

부록

LSH 17.06.23

List of Tables

List of Tables

  • Number of Products under Development for Nephrotic Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Nephrotic Syndrome - Pipeline by Adare Pharma Solutions, 2021
  • Nephrotic Syndrome - Pipeline by APIE Therapeutics Inc, 2021
  • Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, 2021
  • Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Co, 2021
  • Nephrotic Syndrome - Pipeline by ChemoCentryx Inc, 2021
  • Nephrotic Syndrome - Pipeline by Energenesis Biomedical Co Ltd, 2021
  • Nephrotic Syndrome - Pipeline by Evergreen Therapeutics Inc, 2021
  • Nephrotic Syndrome - Pipeline by Ninevah Therapeutics SL, 2021
  • Nephrotic Syndrome - Pipeline by Pharmapraxis, 2021
  • Nephrotic Syndrome - Pipeline by SynAct Pharma AB, 2021
  • Nephrotic Syndrome - Dormant Projects, 2021

List of Figures

List of Figures

  • Number of Products under Development for Nephrotic Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Drugs In Development, 2021, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema), foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.

Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Nephrotic Syndrome - Overview
  • Nephrotic Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Nephrotic Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Nephrotic Syndrome - Companies Involved in Therapeutics Development
  • Adare Pharma Solutions
  • APIE Therapeutics Inc
  • Asahi Kasei Pharma Corp
  • Bristol-Myers Squibb Co
  • ChemoCentryx Inc
  • Energenesis Biomedical Co Ltd
  • Evergreen Therapeutics Inc
  • Ninevah Therapeutics SL
  • Pharmapraxis
  • SynAct Pharma AB
  • Nephrotic Syndrome - Drug Profiles
  • abatacept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AP-1189 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APT-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EG-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ENERGIF-710 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ilacirnon sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • mizoribine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NTX-014 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • prednisone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Nephrotic Syndrome - Dormant Projects
  • Nephrotic Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Aug 25, 2021: SynAct strengthens IP portfolio - Grant of key European patent covering AP1189
  • Jun 29, 2020: SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
  • Jun 02, 2020: SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
  • Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
  • Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q